Estrella Immunopharma, Inc. 10-Q

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS The following table provides information with respect to repurchases of our Common Stock during each month of the quarter ended September 30, 2024. 8 Issuer Purchases of Common Stock (i) Period Total Number of Shares Purchased Average Price Paid Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Maximum Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs July 1, 2024 – July 31, 2024 98,180 $ 1.40 419,974 $ 508,482 August 1, 2024 – August 31, 2024 0 $ 0 419,974 $ 508,482 September 1, 2024 – September 30, 2024 11,749 $ 1.14 431,723 $ 495,096 Total 109,929 (i) All shares of Common Stock repurchased during the quarter ended September 30, 2024 were made in open-market transactions pursuant to the authorization of the Company’s board of directors to repurchase up to $1,000,000 of the Company’s common stock as publicly announced in the Company’s press release issued on January 30, 2024 and included as Exhibit 99.1 to the Company’s Current Report on Form 8-K filed on the same date. The authorization does not have an expiration date. While the Company anticipates as of the date hereof that it will continue to repurchase shares of Common Stock pursuant to the authorization, the Company is not obligated to repurchase any particular amount of Common Stock pursuant to the authorization and the timing, method and amount of any repurchases made pursuant to the authorization in the future may depend on market conditions and other factors. ITEM 3. DEFAULTS UPON SENIOR SECURITIES None. ITEM 4. MINE SAFETY DISCLOSURES Not applicable.